Valuation AstraZeneca PLC NYSE

Stocks

Market Closed - NYSE Other stock markets 00:00:02 13/06/2026 +04			5-day change	1st Jan Change
178.75 ^USD	-1.94%		-3.87%	+94.44%

06-13	Astrazeneca TRUQAP Combination Approves in the US as First and Only Targeted Treatment for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer	CI
06-13	AstraZeneca says Truqap combination approved in US for prostate cancer	AN

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	182,034	209,442	209,268	203,171	287,813	280,262	-	-
Change	-	15.06%	-0.08%	-2.91%	41.66%	-2.62%	-	-
Enterprise Value (EV) ¹	206,417	232,365	231,778	227,741	311,187	299,858	292,929	285,526
Change	-	12.57%	-0.25%	-1.74%	36.64%	-3.64%	-2.31%	-2.53%
P/E Ratio	1,469x	64.1x	35.4x	29.1x	28.4x	22.8x	19.8x	17.2x
PBR	4.24x	5.65x	5.39x	5.02x	5.96x	5.27x	4.54x	3.71x
PEG	-	0x	0.4x	1.6x	0.6x	1.1x	1.3x	1.1x
Capitalization / Revenue	4.87x	4.72x	4.57x	3.76x	4.9x	4.43x	4.17x	3.92x
EV / Revenue	5.52x	5.24x	5.06x	4.21x	5.3x	4.74x	4.36x	3.99x
EV / EBITDA	27.2x	25.2x	17.1x	13.6x	16x	13.5x	12x	10.7x
EV / EBIT	20.8x	17.4x	15.9x	13.5x	16.8x	14.1x	12.4x	11x
EV / FCF	42.4x	26.7x	25.8x	22.9x	26.5x	28.7x	21.3x	18.8x
FCF Yield	2.36%	3.75%	3.88%	4.36%	3.78%	3.48%	4.69%	5.33%
Dividend per Share ²	2.87	2.9	2.9	3.1	3.2	3.337	3.524	3.659
Rate of return	2.44%	2.15%	2.15%	2.37%	1.72%	1.85%	1.95%	2.02%
EPS ²	0.08	2.11	3.81	4.5	6.54	7.933	9.115	10.53
Distribution rate	3,588%	137%	76.1%	68.9%	48.9%	42.1%	38.7%	34.7%
Net sales ¹	37,417	44,351	45,811	54,073	58,739	63,323	67,156	71,557
EBITDA ¹	7,586	9,237	13,580	16,691	19,476	22,259	24,405	26,592
EBIT ¹	9,928	13,350	14,534	16,928	18,478	21,242	23,588	25,913
Net income ¹	112	3,288	5,961	7,035	10,225	12,429	14,086	16,010
Net Debt ¹	24,383	22,923	22,510	24,570	23,374	19,596	12,668	5,264
Reference price ²	117.51	135.16	135.02	131.05	185.60	180.70	180.70	180.70
Nbr of stocks (in thousands)	1,549,159	1,549,528	1,549,926	1,550,317	1,550,726	1,550,996	-	-
Announcement Date	10/02/22	09/02/23	08/02/24	06/02/25	10/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	33.15x	12.05x	24.81x	0.6%	1,010B
JOHNSON & JOHNSON	25.74x	5.93x	16.13x	2.22%	580B
ABBVIE INC.	27.88x	6.79x	13.86x	3.01%	402B
ROCHE HOLDING AG	17.71x	4.37x	10.73x	3.04%	330B
NOVARTIS AG	21.24x	5.49x	13.32x	2.92%	281B
NOVO NORDISK A/S	12.7x	4.76x	9.73x	3.95%	197B
AMGEN INC.	23.09x	6.16x	10.76x	2.84%	192B
GILEAD SCIENCES, INC.	-45x	5.43x	29.95x	2.58%	156B
PFIZER INC.	12.26x	3.2x	7.8x	6.68%	149B
Average	14.31x	6.02x	15.23x	3.09%	366.45B
Weighted average by Cap.	22.20x	7.51x	17.31x	2.32%